According to Novartis, Entresto is the first and only angiotensin receptor-neprilysin inhibitor (ARNi) currently FDA-approved for use in the US for the treatment of heart failure and has no ...

Scarring of heart tissue can be slowed but not stopped, and can lead to heart failure. But a new study has shown that an ...

A study by researchers at Saint Louis University shows that only one in eight patients with heart failure in the United ...

Disclaimer: The information provided here is latest and updated as available from India Post, but the users are advised to verify information with the respective Postal Office before using the ...

A new AI-enhanced ECG model, AIRE, accurately predicts mortality and heart disease risk, providing clinicians with actionable ...

Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Experimental Drug Engineered to Prevent Heart Failure After Heart Attacks Oct. 24, 2024 — An experimental therapeutic monoclonal antibody therapy could become the first to directly enhance ...

In about 50% of cases, myocarditis leads to dangerous heart problems like irregular heartbeat and heart failure, the ...

The OSU research team used the dietary inflammatory index, a tool developed a decade ago that includes 45 dietary components, ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...